Cargando…
Epigenetic Drug Discovery /
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Weinhem, Germany :
Wiley-VCH,
2018.
©2019 |
| Colección: | Methods and Principles in Medicinal Chemistry Ser.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_on1080074581 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 181222s2018 gw o 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d YDX |d MDU |d OCLCQ |d REDDC |d OCLCO |d OCLCL | ||
| 019 | |a 1079428260 |a 1085698552 |a 1086061650 | ||
| 020 | |a 9783527809264 | ||
| 020 | |a 3527809260 | ||
| 020 | |z 3527343148 | ||
| 020 | |z 9783527343140 | ||
| 035 | |a (OCoLC)1080074581 |z (OCoLC)1079428260 |z (OCoLC)1085698552 |z (OCoLC)1086061650 | ||
| 050 | 4 | |a RM301.3.G45 |b .E654 2019 | |
| 082 | 0 | 4 | |a 615.7 |q OCoLC |2 23/eng/20230216 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Epigenetic Drug Discovery / |c edited by Wolgang Sippl and Manfred Jung. |
| 260 | |a Weinhem, Germany : |b Wiley-VCH, |c 2018. | ||
| 264 | 4 | |c ©2019 | |
| 300 | |a 1 online resource (506 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Methods and Principles in Medicinal Chemistry Ser. | |
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Cover; Title Page; Copyright; Preface; Foreword; Contents; Part I Introduction -- Epigenetics; Chapter 1 Epigenetics: Moving Forward; 1.1 Why This Enormously Increased Interest?; 1.2 Looking Forward to New Avenues of Epigenetics; Acknowledgments; References; Part II General Aspects/Methodologies; Chapter 2 Structural Biology of Epigenetic Targets: Exploiting Complexity; 2.1 Introduction; 2.2 DNA Methylases: The DNMT3A-DNMT3L-H3 and DNMT1-USP7 Complexes; 2.3 Histone Arginine Methyltransferases: The PRMT5-MEP50 Complex | |
| 505 | 2 | |a 2.4 Histone Lysine Methyltransferases: The MLL3-RBBP5-ASH2L and the PRC2 Complexes2.5 Histone Lysine Ubiquitinylases: The PRC1 Complex; 2.6 Histone Lysine Deubiquitinylases: The SAGA Deubiquitination Module; 2.7 Histone Acetyltransferases: The MSL1 and NUA4 Complexes; 2.8 Histone Deacetylases: HDAC1-MTA1 and HDAC3-SMRT Complexes and HDAC6; 2.9 Histone Variants and Histone Chaperones: A Complex and Modular Interplay; 2.10 ATP-Dependent Remodelers: CHD1, ISWI, SNF2, and the SNF2-Nucleosome Complex | |
| 505 | 2 | |a 2.11 Epigenetic Readers: Histone Crotonylation Readers and the 53BP1-Nucleosome (H2AK15Ub-H4K20me2) Complex2.12 Conclusions; Acknowledgments; References; Chapter 3 Computer-based Lead Identification for Epigenetic Targets; 3.1 Introduction; 3.2 Computer-based Methods in Drug Discovery; 3.2.1 Pharmacophore-based Methods; 3.2.2 QSAR; 3.2.3 Docking; 3.2.4 Virtual Screening; 3.2.5 Binding Free Energy Calculation; 3.3 Histone Deacetylases; 3.3.1 Zinc-Dependent HDACs; 3.3.2 Sirtuins; 3.4 Histone Methyltransferases; 3.5 Histone Demethylases; 3.5.1 LSD1 (KDM1A); 3.5.2 Jumonji Histone Demethylases | |
| 505 | 2 | |a 3.6 SummaryAcknowledgments; References; Chapter 4 Mass Spectrometry and Chemical Biology in Epigenetics Drug Discovery; 4.1 Introduction: Mass Spectrometry Technology Used in Epigenetic Drug Discovery; 4.1.1 Mass Spectrometry Workflows for the Analysis of Proteins; 4.1.2 Mass Spectrometry Imaging; 4.2 Target Identification and Selectivity Profiling: Chemoproteomics; 4.2.1 Histone Deacetylase and Acetyltransferase Chemoproteomics; 4.2.2 Bromodomain Chemoproteomics; 4.2.3 Demethylase Chemoproteomics; 4.2.4 Methyltransferase Chemoproteomics | |
| 505 | 2 | |a 4.3 Characterization of Epigenetic Drug Target Complexes and Reader Complexes Contributing to Drug's Mode of Action4.3.1 Immunoaffinity Purification of Native Protein Complexes; 4.3.2 Immunoaffinity Purification with Antibodies Against Epitope Tags; 4.3.3 Affinity Enrichment Using Histone Tail Peptides as Bait; 4.4 Elucidation of a Drug's Mode of Action: Analysis of Histone Posttranslational Modifications by MS-Based Proteomics; 4.4.1 Histone Modification MS Workflows; 4.4.2 Application of Histone MS Workflows to Characterize Epigenetic Drugs; 4.5 Challenges and New Trends | |
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Pharmacogenomics. | |
| 650 | 6 | |a Pharmacogénomique. | |
| 700 | 1 | |a Sippl, Wolfgang, |e editor. | |
| 700 | 1 | |a Jung, Manfred, |e editor. | |
| 758 | |i has work: |a Epigenetic drug discovery (Text) |1 https://id.oclc.org/worldcat/entity/E39PCGkfm7xm68XWXDwqrR9mtX |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Sippl, Wolfgang. |t Epigenetic Drug Discovery. |d Newark : John Wiley & Sons, Incorporated, ©2018 |z 9783527343140 |
| 830 | 0 | |a Methods and Principles in Medicinal Chemistry Ser. | |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=5613288 |z Texto completo |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL5613288 | ||
| 938 | |a YBP Library Services |b YANK |n 15896433 | ||
| 938 | |a YBP Library Services |b YANK |n 16044769 | ||
| 994 | |a 92 |b IZTAP | ||